Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 67%
Buy 22%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Liquidia Corp has demonstrated a positive outlook based on the substantial increase in estimated sales for its product YUTREPIA, now projected at $1.7B-$2B due to a stronger than expected launch ramp in addressing pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company achieved operating profitability in the first full quarter following YUTREPIA's launch, reflecting its competitive positioning enhanced by the favorable 24-week patient assessment outcomes. Additionally, the promising Phase 3 data for L606 indicates a favorable tolerability profile, bolstering the company's prospects in the biopharmaceutical market.

Bears say

Liquidia Corp faces considerable legal risks that could threaten the exclusivity of YUTREPIA, its primary growth driver, which may impede the company’s top-line revenue potential. Ongoing litigation concerning patent infringement and trade secret misappropriation poses significant downside risks to Liquidia's shares, particularly if unfavorable judgments are rendered that impair YUTREPIA's market presence. Additionally, while the expiration of certain patents may provide a clearer timeline for some legal challenges, the potential for interrupted sales and revenue continuity underscores the company's current valuation discount relative to its growth prospects.

LQDA has been analyzed by 9 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 9 analysts, LQDA has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.